Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, García-Sastre A, Krammer F, Nachbagauer R, Palese P, Solórzano A, Bi D, David MP, Friel D, Innis BL, Koch J, Mallett CP, Rouxel RN, Salaun B, Vantomme V, Verheust C, Struyf F. Folschweiller N, et al. Among authors: chu l. Lancet Infect Dis. 2022 Jul;22(7):1062-1075. doi: 10.1016/S1473-3099(22)00024-X. Epub 2022 Apr 21. Lancet Infect Dis. 2022. PMID: 35461522 Clinical Trial.
A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.
Langley JM, Frenette L, Chu L, McNeil S, Halperin S, Li P, Vaughn D. Langley JM, et al. Among authors: chu l. BMC Infect Dis. 2012 Oct 30;12:279. doi: 10.1186/1471-2334-12-279. BMC Infect Dis. 2012. PMID: 23110320 Free PMC article. Clinical Trial.
Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
Langley JM, Frenette L, Jeanfreau R, Halperin SA, Kyle M, Chu L, McNeil S, Dramé M, Moris P, Fries L, Vaughn DW. Langley JM, et al. Among authors: chu l. Vaccine. 2015 Jan 15;33(4):559-67. doi: 10.1016/j.vaccine.2014.11.018. Epub 2014 Nov 21. Vaccine. 2015. PMID: 25448092 Free article. Clinical Trial.
Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial.
Jain VK, Domachowske JB, Wang L, Ofori-Anyinam O, Rodríguez-Weber MA, Leonardi ML, Klein NP, Schlichter G, Jeanfreau R, Haney BL, Chu L, Harris JS, Sarpong KO, Micucio AC, Soni J, Chandrasekaran V, Li P, Innis BL. Jain VK, et al. Among authors: chu l. J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):9-19. doi: 10.1093/jpids/piw068. J Pediatric Infect Dis Soc. 2017. PMID: 28062552 Free PMC article. Clinical Trial.
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
Beran J, Lickliter JD, Schwarz TF, Johnson C, Chu L, Domachowske JB, Van Damme P, Withanage K, Fissette LA, David MP, Maleux K, Schmidt AC, Picciolato M, Dieussaert I. Beran J, et al. Among authors: chu l. J Infect Dis. 2018 Apr 23;217(10):1616-1625. doi: 10.1093/infdis/jiy065. J Infect Dis. 2018. PMID: 29401325 Free PMC article. Clinical Trial.
Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study.
Standaert B, Dort T, Linden J, Madan A, Bart S, Chu L, Hayney MS, Kosinski M, Kroll R, Malak J, Meier G, Segall N, Schuind A. Standaert B, et al. Among authors: chu l. Health Qual Life Outcomes. 2019 May 6;17(1):80. doi: 10.1186/s12955-019-1147-4. Health Qual Life Outcomes. 2019. PMID: 31060567 Free PMC article.
Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.
Frenck RW Jr, Ervin J, Chu L, Abbanat D, Spiessens B, Go O, Haazen W, van den Dobbelsteen G, Poolman J, Thoelen S, Ibarra de Palacios P. Frenck RW Jr, et al. Among authors: chu l. Lancet Infect Dis. 2019 Jun;19(6):631-640. doi: 10.1016/S1473-3099(18)30803-X. Epub 2019 May 9. Lancet Infect Dis. 2019. PMID: 31079947 Clinical Trial.
3,125 results